Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives Average Rating of “Buy” from Analysts

Centessa Pharmaceuticals plc (NASDAQ:CNTA) has earned a consensus recommendation of “Buy” from the six brokerages that are presently covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $25.17.

Several brokerages have commented on CNTA. BMO Capital Markets lifted their target price on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a report on Monday, September 16th. Oppenheimer reiterated an “outperform” rating and issued a $14.00 target price on shares of Centessa Pharmaceuticals in a report on Wednesday, August 14th. Guggenheim raised their price target on shares of Centessa Pharmaceuticals from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. Morgan Stanley raised shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $11.00 to $26.00 in a research note on Thursday, September 19th. Finally, B. Riley initiated coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, September 19th. They set a “buy” rating and a $33.00 target price for the company.

Insider Activity

In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 175,000 shares of the firm’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $16.52, for a total value of $2,891,000.00. Following the completion of the sale, the chief executive officer now directly owns 776,924 shares in the company, valued at $12,834,784.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 175,000 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $16.52, for a total value of $2,891,000.00. Following the transaction, the chief executive officer now owns 776,924 shares in the company, valued at $12,834,784.48. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Gregory M. Weinhoff sold 12,198 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $12.17, for a total value of $148,449.66. Following the completion of the sale, the insider now directly owns 241,171 shares of the company’s stock, valued at approximately $2,935,051.07. The disclosure for this sale can be found here. Insiders sold 271,873 shares of company stock worth $4,381,150 in the last quarter. 11.59% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in CNTA. Quarry LP raised its holdings in shares of Centessa Pharmaceuticals by 47.8% in the 2nd quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after acquiring an additional 3,108 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Centessa Pharmaceuticals by 69.2% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 10,817 shares of the company’s stock worth $122,000 after purchasing an additional 4,423 shares in the last quarter. EntryPoint Capital LLC purchased a new stake in shares of Centessa Pharmaceuticals in the first quarter worth approximately $109,000. Sandia Investment Management LP bought a new position in shares of Centessa Pharmaceuticals in the second quarter valued at approximately $90,000. Finally, Fred Alger Management LLC purchased a new position in shares of Centessa Pharmaceuticals during the second quarter valued at approximately $99,000. 82.01% of the stock is owned by institutional investors.

Centessa Pharmaceuticals Stock Performance

Centessa Pharmaceuticals stock opened at $15.34 on Thursday. The business has a 50 day moving average of $12.76 and a 200-day moving average of $10.77. The company has a debt-to-equity ratio of 0.27, a current ratio of 13.29 and a quick ratio of 13.29. Centessa Pharmaceuticals has a 1 year low of $5.15 and a 1 year high of $17.59. The company has a market capitalization of $1.54 billion, a P/E ratio of -10.80 and a beta of 1.44.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.02). On average, equities research analysts predict that Centessa Pharmaceuticals will post -1.62 earnings per share for the current year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.